Clinical trials: Neoplasm, Brain
Cerebral Tumor
Evaluation of the Interest of Ultra-high Frequency Doppler Ultrasound (UFDU) in the Surgical Management of Patients Operated in an Awake Condition for a Cerebral Tumor
In brain tumor surgery we are confronted mainly with two types of difficulties: (i) the identification of the tumor and its limitations in relation to the healthy brain; (ii) the identification of functional cerebral regions, ie…
- Trial name
- EUHF_PRC (NCT03179176)
- Testing
- High Frequence Ultrasound Doppler (HFUD) utilisation
- Where
- France
- Volunteers
- 4 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Glioblastoma, Brain Neoplasms
NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
This pilot phase II trial studies how well Novocure's Tumor Treating Electric Fields (NovoTTF) therapy works in treating patients with recurrent glioblastoma multiforme.
- Trial name
- NCT01954576
- Testing
- NovoTTF-100A, Quality-of-life assessment, Laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of Florida
Melanoma (Skin)
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
To learn if giving nivolumab in combination with relatlimab can help to control melanoma that has spread to the brain (melanoma with brain metastases).
- Trial name
- NCT05704647
- Testing
- BMS-986213 (Relatlimab-Nivolumab FDC), Nivolumab, Relatlimab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
ARDS (Moderate or Severe)
Prone Positioning in ARDS: Predicting Neurological Complications Via Cerebral Hemodynamics
Prone Positioning in ARDS: Predicting Neurological Complications via Cerebral Hemodynamics
- Trial name
- PRONEBRAINAR (NCT06967285)
- Testing
- Prone ventilation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sichuan Provincial People's Hospital
Brain and Central Nervous System Tumors
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006025
- Testing
- irinotecan hydrochloride, temozolomide
- Where
- 9 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Seizures, Brain Tumor
Levetiracetam Prophylaxis in Brain Tumor Resection Pilot
This study aims to evaluate feasibility of a double-blind randomized controlled trial for levetiracetam prophylaxis for prevention of seizure in the perioperative phase of brain tumor resection.
- Trial name
- LeviTaTe Pilot (NCT05897658)
- Testing
- Levetiracetam
- Volunteers
- 70 people
- Sponsor
- Hamilton Health Sciences Corporation
ALK-positive Non-small Cell Lung Cancer, Brain Metastases
A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis
This study was a retrospective observational study. The study included patients with non-small cell lung cancer with ALK-fusion brain metastases or meningeal metastases who received first-line and late-line treatment with the…
- Conditions
- ALK-positive Non-small Cell Lung Cancer, Brain Metastases, Meningeal Metastasis
- Trial name
- NCT06410040
- Testing
- Lorlatinib
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Solid Tumor, Leukemia
Illness Management and Parental Adjustment to Cancer Treatment
The purpose of this study is to test the efficacy of a clinic-based intervention designed to reduce illness uncertainty for parents of children who have been recently diagnosed with cancer.
- Conditions
- Solid Tumor, Leukemia, Lymphoma, Brain Tumor
- Trial name
- IMPACT (NCT02505165)
- Testing
- IMPACT, ESO
- Where
- 3 sites in United States
- Volunteers
- 279 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Brain and Central Nervous System Tumors
Imatinib Mesylate in Treating Patients With Gliomas
RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and slow the growth of the tumor. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have gliomas.
- Trial name
- NCT00039364
- Testing
- imatinib mesylate
- Where
- 10 sites in Austria, Belgium and 5 more
- Volunteers
- 112 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Pituitary Diseases, Pituitary Neoplasms
Long Term Outcome Study in Patients With Pituitary Disorders
To determine the outcomes of patients with different pituitary disorders whether they are managed medically, surgically or expectantly.
- Trial name
- NCT03665064
- Volunteers
- 1,500 people
- Sponsor
- University of Alberta
Brain Metastases, CNS Metastases
Electrochemotherapy as a Palliative Treatment for Brain Metastases
Because electrochemotherapy is a quick and effective treatment for cutaneous metastases, a novel electrode device has been developed for treatment in soft tissue such as the brain.
- Trial name
- NCT01322100
- Testing
- The Electroporation System, Bleomycin
- Where
- 2 sites in Denmark
- Volunteers
- 1 people
- Sponsor
- Copenhagen University Hospital at Herlev
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
This phase I/II clinical trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 and to see how well it works in treating young patients with relapsed or refractory solid tumors, CNS tumors…
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor
- Trial name
- NCT01088763
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study
- Where
- 12 sites in United States, Canada
- Volunteers
- 129 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer, Brain Metastases
Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases
This study is to find out if administration of stereotactic radiosurgery (SRS) given after Nivolumab will improve overall response rate/anti-tumor activity in patients with metastatic breast cancer with brain metastases.
- Trial name
- NCT03807765
- Testing
- Nivolumab, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Brain Metastases, CNS Neoplasm
HyperArc Registry Study
The HyperArc registry is designed to collect data from which the efficacy of the HyperArc procedure can be assessed and compared to alternative treatments.
- Conditions
- Brain Metastases, CNS Neoplasm, CNS Disorder, Intracranial
- Trial name
- NCT05270707
- Testing
- Stereotactic radiosurgery
- Where
- 7 sites in United States, Australia and 2 more
- Volunteers
- 968 people
- Sponsor
- Varian, a Siemens Healthineers Company
Brain and Central Nervous System Tumors
Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma
RATIONALE: Thalidomide may stop the growth of malignant glioma by stopping blood flow to the tumor. Drugs used in chemotherapy, such as procarbazine, work in different ways to stop tumor cells from dividing so they stop growing…
- Trial name
- NCT00079092
- Testing
- procarbazine hydrochloride, thalidomide
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Wake Forest University Health Sciences
Esophageal Neoplasms, Esophagectomy
Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)
Esophagectomy is the cornerstone of the curative treatment of esophageal carcinoma. Despite this treatment, patients can suffer from locoregional or distant metastatic disease and only a very selected group of patients can be…
- Conditions
- Esophageal Neoplasms, Esophagectomy, Brain Metastases
- Trial name
- METABREC (NCT04654975)
- Testing
- Esophagectomy for esophageal cancer
- Where
- 8 sites in United States, Belgium and 4 more
- Volunteers
- 10,000 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
This phase I/II trial is studying the side effects and best dose of erlotinib, tipifarnib, and temsirolimus when given together with sorafenib and to see how well they work in treating patients with recurrent glioblastoma…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00335764
- Testing
- sorafenib tosylate, erlotinib hydrochloride, tipifarnib
- Where
- 7 sites in United States
- Volunteers
- 92 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma (GBM), Brain Metastasases
A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases
This will be an open-label Phase 0/1 study that will enroll approximately 15 participants, 9 participants with recurrent WHO Grade 4 glioma (rGBM) and 6 participants with brain metastases, who will receive the investigational…
- Trial name
- NCT07268053
- Testing
- Risvutatug rezetecan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Nader Sanai
Melanoma and Brain Metastases
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain
This study is designed to assess the efficacy, pharmacokinetics, safety, and tolerability of an oral, twice daily dose of 150 mg GSK2118436 administered to subjects with BRAF V600E or V600K mutation-positive metastatic melanoma…
- Trial name
- Break MB (NCT01266967)
- Testing
- GSK2118436
- Where
- 24 sites in United States, Australia and 4 more
- Volunteers
- 172 people
- Sponsor
- GlaxoSmithKline
Brain and Central Nervous System Tumors, Endometrial Cancer
Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have…
- Conditions
- Brain and Central Nervous System Tumors, Endometrial Cancer, Gastrointestinal Stromal Tumor, Ovarian Cancer
- Trial name
- NCT00003939
- Testing
- trabectedin
- Volunteers
- 132 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.